Multivirus-specific cytotoxic T lymphocytes - ViraCyteAlternative Names: Multivirus-specific cytotoxic T lymphocyte therapy
Latest Information Update: 15 Dec 2016
At a glance
- Originator Baylor College of Medicine
- Class Antivirals; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Herpesvirus infections; Polyomavirus infections